Bristol-Myers Squibb
Bristol Myers Squibb to acquire RayzeBio for $4.1 billion in cash
31 Dec 2023
American multinational pharmaceutical company Bristol Myers Squibb on Tuesday said it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business
Bristol-Myers to acquire Celgene in $74-bn cash-and-stock deal
03 Jan 2019
Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 per cent to Celgene’s Wednesday close, besides one tradable contingent value right for each share held
GlaxoSmithKline’s majority-owned HIV business to buy drugs from US rival Bristol-Myers Squibb
18 Dec 2015
Drugmaker Bristol-Myers Squibb acquires rights to Promedior Inc and its experimental drug PRM-151
01 Sep 2015
Health ministry seeks compulsory licence for Bristol-Myers' cancer drug
03 Apr 2014
A month’s dosage of Bristol-Myers Squibb’s patented drug Dasatinib, which is sold under the brand name `Sprycel’, costs around Rs60,000
AstraZeneca to pay Bristol-Myers Squibb $135 mn more for Amylin drug rights
10 Aug 2012
AstraZeneca will pay the $135 million to Bristol-Myers Squibb after the anti-trust and other competition regulators approve the acquisition of Amylin
